New Enterprise Associates

ForAllSecure specializes in advanced fuzz testing and autonomous cybersecurity solutions, leveraging patented technology developed through extensive research at Carnegie Mellon University. The company collaborates with Fortune 1000 clients across sectors such as aerospace, automotive, and high-tech to deliver scalable security testing that adapts to rapid development and deployment cycles. Its innovative approach employs automated program analysis and artificial intelligence to identify and resolve software vulnerabilities in real-time, thereby enhancing the security posture of organizations. Recognized for its achievements, ForAllSecure won DARPA's Cyber Grand Challenge and was highlighted by MIT Technology Review as one of the 50 Smartest Companies.

Belong Health works with local health plans to provide regionally informed, humanistic care to a rapidly expanding community of need.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet the multiple anatomical challenges presented by vein mechanics. Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA.

Lungpacer Medical Inc. is a medical device company specializing in therapeutic solutions aimed at enhancing the treatment of critically ill patients who require mechanical ventilation. Founded in 2009 and headquartered in Vancouver, Canada, with an additional office in Exton, Pennsylvania, the company has developed the Lungpacer DPT System. This diaphragm pacing system utilizes a temporary, minimally invasive, transvascular nerve stimulation technique to activate the diaphragm muscle, preserving its strength and integrity. By addressing the significant health and cost challenges associated with mechanical ventilation in Intensive Care Units, Lungpacer Medical aims to improve patient outcomes and reduce hospital care costs. The technology is designed to restore negative pressure ventilation, offering a more physiological respiratory pattern and mitigating the harmful effects associated with positive pressure ventilation.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Nth Round is a technology company that specializes in equity management solutions. Its platform is designed to help modern CFOs streamline investor workflows by simplifying the management of equity, distributing reports, and engaging shareholders securely. The company provides tools for cap table management, reporting, and custom templates, all accessible from a single secure portal. Additionally, Nth Round's technology helps reduce the administrative complexity associated with ownership, enabling private companies and fund owners to effectively manage and track their equity and ownership structures.

Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet the multiple anatomical challenges presented by vein mechanics. Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Curalate, Inc. operates an online platform that helps brands facilitate consumer discovery and purchase decisions. The platform transforms images and videos into digital storefronts across websites, social media, advertisements, and emails. Curalate provides tools for brands to link products from social media, automate content posting, and gain insights into engagement metrics. Additionally, it allows brands to monitor their campaigns, competitors, and influencers. Founded in 2011 and based in Philadelphia, Pennsylvania, with offices in New York, Seattle, and London, Curalate serves hundreds of leading brands, including Gap, Neiman Marcus, and Sephora. The company's services enhance the connection between off-site discovery and on-site conversion, driving revenue growth on platforms such as Pinterest, Instagram, and Facebook. Curalate was previously known as Storably, Inc. and became a subsidiary of Bazaarvoice, Inc. in July 2020.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Duolingo, Inc. is a language-learning platform founded in 2011 and headquartered in Pittsburgh, Pennsylvania. The company offers a free service that enables users to learn nearly 40 languages through 98 distinct courses, with an option for a premium subscription that provides additional features such as ad removal and offline access. Duolingo claims to have 30 million active users, making it a leading educational app globally. It also provides tailored solutions for educators through "Duolingo for Schools," which allows teachers to monitor student progress. The platform utilizes advanced data analytics and artificial intelligence to enhance the learning experience, incorporating engaging design elements to keep users motivated. Duolingo's revenue primarily derives from subscriptions, and it has emerged as a top-grossing app in the education category on both Google Play and the Apple App Store.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Uber is a technology company that operates a ridesharing mobile application, connecting riders with partner drivers in over 300 cities globally. Founded in 2009, Uber has transformed urban mobility by making transportation more accessible and efficient. Users can submit trip requests through the app, which then routes these requests to nearby drivers, facilitating transportation arrangements in real time. In addition to its core ridesharing services, Uber is also advancing into the realm of autonomous vehicles through its Uber Advanced Technologies Group, which focuses on developing self-driving technology aimed at providing safe and reliable transportation. Furthermore, Uber Elevate is exploring the future of aerial ridesharing, collaborating with various stakeholders to establish a framework for air travel innovation. Overall, Uber's operations encompass a diverse range of transportation solutions, enhancing the connectivity of cities and their inhabitants.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Curalate, Inc. operates an online platform that helps brands facilitate consumer discovery and purchase decisions. The platform transforms images and videos into digital storefronts across websites, social media, advertisements, and emails. Curalate provides tools for brands to link products from social media, automate content posting, and gain insights into engagement metrics. Additionally, it allows brands to monitor their campaigns, competitors, and influencers. Founded in 2011 and based in Philadelphia, Pennsylvania, with offices in New York, Seattle, and London, Curalate serves hundreds of leading brands, including Gap, Neiman Marcus, and Sephora. The company's services enhance the connection between off-site discovery and on-site conversion, driving revenue growth on platforms such as Pinterest, Instagram, and Facebook. Curalate was previously known as Storably, Inc. and became a subsidiary of Bazaarvoice, Inc. in July 2020.

Duolingo, Inc. is a language-learning platform founded in 2011 and headquartered in Pittsburgh, Pennsylvania. The company offers a free service that enables users to learn nearly 40 languages through 98 distinct courses, with an option for a premium subscription that provides additional features such as ad removal and offline access. Duolingo claims to have 30 million active users, making it a leading educational app globally. It also provides tailored solutions for educators through "Duolingo for Schools," which allows teachers to monitor student progress. The platform utilizes advanced data analytics and artificial intelligence to enhance the learning experience, incorporating engaging design elements to keep users motivated. Duolingo's revenue primarily derives from subscriptions, and it has emerged as a top-grossing app in the education category on both Google Play and the Apple App Store.

Scratch Music Group, Inc. operates as a music and technology company, primarily through its Scratch DJ Academy, which offers DJ and music production education across multiple major cities in the United States, including New York, Miami, Los Angeles, Atlanta, and Chicago, as well as numerous satellite locations in hotels, resorts, and on cruise ships globally. Founded in 2002 by Jam Master Jay of Run DMC, the academy has taught over 500,000 individuals using a proprietary curriculum. In addition to educational services, Scratch Music Group creates immersive events for prominent brands, having successfully collaborated with clients like H&M, MTV, and Pepsi. Their Scratch Weddings division provides high-quality DJ services tailored to modern couples, ensuring a distinct and professional musical experience for weddings. With nearly 100,000 events executed and over 15 million guests entertained in more than 25 countries, Scratch Music Group has established a notable presence in the music and events industry, gaining recognition from various media outlets including CNN, The New York Times, and Forbes.

Scratch Music Group, Inc. operates as a music and technology company, primarily through its Scratch DJ Academy, which offers DJ and music production education across multiple major cities in the United States, including New York, Miami, Los Angeles, Atlanta, and Chicago, as well as numerous satellite locations in hotels, resorts, and on cruise ships globally. Founded in 2002 by Jam Master Jay of Run DMC, the academy has taught over 500,000 individuals using a proprietary curriculum. In addition to educational services, Scratch Music Group creates immersive events for prominent brands, having successfully collaborated with clients like H&M, MTV, and Pepsi. Their Scratch Weddings division provides high-quality DJ services tailored to modern couples, ensuring a distinct and professional musical experience for weddings. With nearly 100,000 events executed and over 15 million guests entertained in more than 25 countries, Scratch Music Group has established a notable presence in the music and events industry, gaining recognition from various media outlets including CNN, The New York Times, and Forbes.

Curalate, Inc. operates an online platform that helps brands facilitate consumer discovery and purchase decisions. The platform transforms images and videos into digital storefronts across websites, social media, advertisements, and emails. Curalate provides tools for brands to link products from social media, automate content posting, and gain insights into engagement metrics. Additionally, it allows brands to monitor their campaigns, competitors, and influencers. Founded in 2011 and based in Philadelphia, Pennsylvania, with offices in New York, Seattle, and London, Curalate serves hundreds of leading brands, including Gap, Neiman Marcus, and Sephora. The company's services enhance the connection between off-site discovery and on-site conversion, driving revenue growth on platforms such as Pinterest, Instagram, and Facebook. Curalate was previously known as Storably, Inc. and became a subsidiary of Bazaarvoice, Inc. in July 2020.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Bravo Health, Inc. is a managed care provider that specializes in offering Medicare Advantage plans, including options tailored for special needs populations such as those receiving institutional care or individuals with chronic health conditions. The company also provides private fee-for-service plans, allowing members the flexibility to choose their healthcare providers, as well as Part D prescription drug plans for those requiring medication coverage. Bravo Health serves members across several states, including Delaware, Maryland, Pennsylvania, Texas, New Jersey, and Washington, D.C., and extends its prescription drug plans to 43 states. Founded in 1996 and based in Baltimore, Maryland, the company was formerly known as Elder Health, Inc.

Duolingo, Inc. is a language-learning platform founded in 2011 and headquartered in Pittsburgh, Pennsylvania. The company offers a free service that enables users to learn nearly 40 languages through 98 distinct courses, with an option for a premium subscription that provides additional features such as ad removal and offline access. Duolingo claims to have 30 million active users, making it a leading educational app globally. It also provides tailored solutions for educators through "Duolingo for Schools," which allows teachers to monitor student progress. The platform utilizes advanced data analytics and artificial intelligence to enhance the learning experience, incorporating engaging design elements to keep users motivated. Duolingo's revenue primarily derives from subscriptions, and it has emerged as a top-grossing app in the education category on both Google Play and the Apple App Store.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Curalate, Inc. operates an online platform that helps brands facilitate consumer discovery and purchase decisions. The platform transforms images and videos into digital storefronts across websites, social media, advertisements, and emails. Curalate provides tools for brands to link products from social media, automate content posting, and gain insights into engagement metrics. Additionally, it allows brands to monitor their campaigns, competitors, and influencers. Founded in 2011 and based in Philadelphia, Pennsylvania, with offices in New York, Seattle, and London, Curalate serves hundreds of leading brands, including Gap, Neiman Marcus, and Sephora. The company's services enhance the connection between off-site discovery and on-site conversion, driving revenue growth on platforms such as Pinterest, Instagram, and Facebook. Curalate was previously known as Storably, Inc. and became a subsidiary of Bazaarvoice, Inc. in July 2020.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.

Vitae Pharmaceuticals is a clinical-stage biotechnology company based in Fort Washington, Pennsylvania, dedicated to discovering and developing novel small molecule drugs for diseases with significant unmet medical needs. Its pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis; VTP-38543, in Phase IIa for atopic dermatitis; and BI 1147560, aimed at treating and preventing Alzheimer's disease. Additionally, the company is developing VTP-34072, which is in Phase II trials for type 2 diabetes, and VTP-38443 for acute coronary syndrome. Vitae Pharmaceuticals employs a structure-based drug-design platform, Contour, to create best-in-class compounds targeting large markets that include chronic kidney disease and atherosclerosis. Established in 2001, the company operates as a subsidiary of Allergan plc.

Rinera Networks is a professional in internet video distribution. It is based in Pittsburgh, Pennsylvania.

Vitae Pharmaceuticals is a clinical-stage biotechnology company based in Fort Washington, Pennsylvania, dedicated to discovering and developing novel small molecule drugs for diseases with significant unmet medical needs. Its pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis; VTP-38543, in Phase IIa for atopic dermatitis; and BI 1147560, aimed at treating and preventing Alzheimer's disease. Additionally, the company is developing VTP-34072, which is in Phase II trials for type 2 diabetes, and VTP-38443 for acute coronary syndrome. Vitae Pharmaceuticals employs a structure-based drug-design platform, Contour, to create best-in-class compounds targeting large markets that include chronic kidney disease and atherosclerosis. Established in 2001, the company operates as a subsidiary of Allergan plc.

TargetRx is a company that assists pharmaceutical and biotech firms by providing valuable insights into the factors influencing product choice and adoption. Their services are designed to support clients throughout the entire product lifecycle, from development to the period after patent expiry. By analyzing physician behavior, TargetRx enables companies to make informed decisions regarding forecasting, product positioning, and promotional strategies for new drug launches. Additionally, they help optimize marketing messages and materials, enhancing campaign effectiveness in the competitive pharmaceutical landscape.

Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.

Vitae Pharmaceuticals is a clinical-stage biotechnology company based in Fort Washington, Pennsylvania, dedicated to discovering and developing novel small molecule drugs for diseases with significant unmet medical needs. Its pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis; VTP-38543, in Phase IIa for atopic dermatitis; and BI 1147560, aimed at treating and preventing Alzheimer's disease. Additionally, the company is developing VTP-34072, which is in Phase II trials for type 2 diabetes, and VTP-38443 for acute coronary syndrome. Vitae Pharmaceuticals employs a structure-based drug-design platform, Contour, to create best-in-class compounds targeting large markets that include chronic kidney disease and atherosclerosis. Established in 2001, the company operates as a subsidiary of Allergan plc.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

Laurel Networks is a company based in Pittsburgh, Pennsylvania, established in 1999, specializing in the development of IP-based multi-service data delivery solutions. The company offers a range of products, including its ST-series Service Edge Routers, which provide Internet-class routing, support for multiple services, broadband subscriber management, and integrated service management. Additionally, Laurel Networks develops ShadeTree System Software, designed to enhance routing and switching performance, as well as the ShadeTree Management Suite, which facilitates the deployment of services for both residential and business customers.

TargetRx is a company that assists pharmaceutical and biotech firms by providing valuable insights into the factors influencing product choice and adoption. Their services are designed to support clients throughout the entire product lifecycle, from development to the period after patent expiry. By analyzing physician behavior, TargetRx enables companies to make informed decisions regarding forecasting, product positioning, and promotional strategies for new drug launches. Additionally, they help optimize marketing messages and materials, enhancing campaign effectiveness in the competitive pharmaceutical landscape.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

TargetRx is a company that assists pharmaceutical and biotech firms by providing valuable insights into the factors influencing product choice and adoption. Their services are designed to support clients throughout the entire product lifecycle, from development to the period after patent expiry. By analyzing physician behavior, TargetRx enables companies to make informed decisions regarding forecasting, product positioning, and promotional strategies for new drug launches. Additionally, they help optimize marketing messages and materials, enhancing campaign effectiveness in the competitive pharmaceutical landscape.

TargetRx is a company that assists pharmaceutical and biotech firms by providing valuable insights into the factors influencing product choice and adoption. Their services are designed to support clients throughout the entire product lifecycle, from development to the period after patent expiry. By analyzing physician behavior, TargetRx enables companies to make informed decisions regarding forecasting, product positioning, and promotional strategies for new drug launches. Additionally, they help optimize marketing messages and materials, enhancing campaign effectiveness in the competitive pharmaceutical landscape.

Laurel Networks is a company based in Pittsburgh, Pennsylvania, established in 1999, specializing in the development of IP-based multi-service data delivery solutions. The company offers a range of products, including its ST-series Service Edge Routers, which provide Internet-class routing, support for multiple services, broadband subscriber management, and integrated service management. Additionally, Laurel Networks develops ShadeTree System Software, designed to enhance routing and switching performance, as well as the ShadeTree Management Suite, which facilitates the deployment of services for both residential and business customers.

PPONEXT is a PPO services company that provides healthcare management and network services. PPONEXT offers access to a network of medical care providers, hospitals, and ancillary facilities to group health, workers' compensation, and other insurance payers in the Midwest, Texas, California, Florida, New Jersey, and Pennsylvania.

InSoft is a provider of collaborative computing, desktop conferencing, and distributed digital video development tools and applications. The company has been called a pioneer in the desktop videoconferencing market and is credited with developing Internet media streaming and VoIP/collaborative software applications that would later be developed into NetscapeConference and NetscapeMedia Server.